Renal Cell Carcinoma
Latest News
Latest Videos
CME Content
More News
Rana McKay, MD, shares advice for community oncologists treating patients with advanced renal cell carcinoma.
Dr Rana McKay discusses the rationale for using cabozantinib with nivolumab and ipilimumab in the COSMIC 313 trial and reviews the adverse events seen with this combination in the COSMIC 313 trial.
Dr Rana McKay reviews key efficacy data from the COSMIC 313 trial and discusses factors that are considered when choosing between IO-TKI or IO-IO combinations.
Dr Rana McKay discusses the efficacy and qualify-of-life data from the 5-year follow-up of the CheckMate 214 trial investigating nivolumab plus ipilimumab in frontline advanced renal cell carcinoma treatment.
Rana McKay, MD, presents the case of a 73-year-old man with advanced renal cell carcinoma, shares her initial impression, and reviews which factors contribute to a patient’s risk status.
Closing out their discussion on advanced RCC, expert hematologist/oncologists offer key takeaways from their discussion and look toward future treatment evolution in the first-line setting.
Shared insight on the data from the COSMIC-313 trial and the potential for first-line triplet regimens in patients with advanced clear cell renal cell carcinoma.
Moshe Ornstein, MD, MA, continues his discussion of I/O-TKI combination regimens by presenting data from the CheckMate 9ER trial.
Moshe Ornstein, MD, MA, shares data from the KEYNOTE-426 clinical trial that set a new standard of care for treatment-naïve metastatic clear cell RCC.
During a case-based roundtable event, Thomas Hutson, DO, PharmD, discussed challenges with treating a 59-year-old woman with clear cell renal cell carcinoma.
Panelists identify second-line treatment options they would consider in advanced clear cell RCC if a patient progresses following first-line therapy.
Expert hematologist/oncologists consider the potential role for adjuvant immunotherapy in patients with advanced clear cell renal cell carcinoma.
Nizar Tannir, MD, presents the case of a 57-year-old patient with intermediate-risk advanced clear cell RCC, and Scott Tykodi, MD, PhD, presents data from the CheckMate 214 trial.
Key opinion leaders discuss the options for patients with advanced clear cell RCC who have higher-risk metastatic disease.
During a live virtual event, Sumanta K. Pal, MD, discussed with participants how their experience with immunotherapy and tyrosine kinase inhibitor therapies aligned with the data from pivotal clinical trials. This is the second of 2 articles based on this event.
Daniel J George, MD, shares his advice for community oncologists and discusses unmet needs when treating patients with advanced renal cell carcinoma.
Dr Daniel J George talks about the quality-of-life outcomes from the CHECKMATE 9ER and how different metastatic scenarios might affect treatment selection.
Dr Daniel J George reviews long term follow up data from the CHECKMATE 9ER and the implications of the data in the treatment paradigm for patients with advanced renal cell carcinoma.
Dr Daniel J George reviews long term follow up data from the CHECKMATE 9ER and the implications of the data in the treatment paradigm for patients with advanced renal cell carcinoma.
An expert oncologist explains how to calculate a patient’s risk status and provides an overview of front-line treatment options for patients with advanced renal cell carcinoma and discusses which factors are considered when choosing appropriate treatment.
Daniel J. George, MD, describes the case of a 68-year-old woman with advanced renal cell carcinoma.
Focused discussion on the selection of first-line therapy for advanced clear cell renal cell carcinoma based on sites of metastasis.
Expert panelists consider the importance of quality of life when selecting first-line treatment regimens for patients with advanced clear cell renal cell carcinoma.
Dr Scott Tykodi muses on how he would alter treatment for a patient with advanced clear cell RCC after side effects develop.
Drs Tannir and Tykodi share their differing views on the effect an IO and a TKI agent have when combined for advanced clear cell RCC treatment.